Compare AKBA & VLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | VLRS |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | Mexico |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 816.9M |
| IPO Year | 2014 | N/A |
| Metric | AKBA | VLRS |
|---|---|---|
| Price | $1.48 | $7.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $6.25 | ★ $8.43 |
| AVG Volume (30 Days) | ★ 5.0M | 450.3K |
| Earning Date | 11-10-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $225,071,000.00 | ★ $2,990,662,000.00 |
| Revenue This Year | $52.38 | N/A |
| Revenue Next Year | $22.45 | $11.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.49 | N/A |
| 52 Week Low | $1.46 | $3.49 |
| 52 Week High | $4.08 | $9.00 |
| Indicator | AKBA | VLRS |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 69.91 |
| Support Level | $1.52 | $7.13 |
| Resistance Level | $1.63 | $6.60 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 1.15 | 98.94 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).